BioAegis raises $3 million

02/8/2013 | American City Business Journals

A funding round has brought in $3 million for biotech startup BioAegis Therapeutics. The company plans to file an investigational new-drug application with the FDA and launch a Phase IIb/III study of human plasma gelsolin, a natural human protein, in preventing the spread of inflammation resulting in multiple organ dysfunction syndrome in intensive care units.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY